Intermittent Purpura Development Associated with Leukocytoclastic Vasculitis Induced by Infliximab for Crohn's Disease
-
- Kishimoto Kenichi
- Department of Internal Medicine II, Shimane University Faculty of Medicine, Japan
-
- Kawashima Kousaku
- Department of Internal Medicine II, Shimane University Faculty of Medicine, Japan
-
- Fukunaga Mai
- Department of Internal Medicine II, Shimane University Faculty of Medicine, Japan
-
- Kotani Satoshi
- Department of Internal Medicine II, Shimane University Faculty of Medicine, Japan
-
- Sonoyama Hiroki
- Department of Internal Medicine II, Shimane University Faculty of Medicine, Japan
-
- Oka Akihiko
- Department of Internal Medicine II, Shimane University Faculty of Medicine, Japan
-
- Mishima Yoshiyuki
- Department of Internal Medicine II, Shimane University Faculty of Medicine, Japan
-
- Oshima Naoki
- Department of Internal Medicine II, Shimane University Faculty of Medicine, Japan
-
- Ishimura Norihisa
- Department of Internal Medicine II, Shimane University Faculty of Medicine, Japan
-
- Ishikawa Noriyoshi
- Department of Pathology, Shimane University Faculty of Medicine, Japan
-
- Maruyama Riruke
- Department of Pathology, Shimane University Faculty of Medicine, Japan
-
- Ishihara Shunji
- Department of Internal Medicine II, Shimane University Faculty of Medicine, Japan
この論文をさがす
抄録
<p>Anti-tumor necrosis factor (TNF) α agents, widely used for the treatment of Crohn's disease (CD), can sometimes induce skin-associated adverse events, which mainly include psoriasis-like eruptions, eczema, and cutaneous infections. In contrast, purpura caused by vasculitis is rarely seen. We herein report a unique case of leukocytoclastic vasculitis induced by infliximab administered for CD in which intermittent purpura development was noted. Fluorescent immunostaining showed no immunoglobulin A deposition on the vessel walls. No purpura was initially seen after starting infliximab, but it appeared approximately 10 months later; however, administration did not have to be discontinued, and the condition was later resolved. The present findings provide important details regarding vasculitis induced by anti-tumor necrosis factor-α agent administration. </p>
収録刊行物
-
- Internal Medicine
-
Internal Medicine 60 (3), 385-389, 2021-02-01
一般社団法人 日本内科学会